The influence of L-arginine and its analogues on the generation of reactive oxygen and nitrogen species by professional phagocytes
Project goals
The aim of the project is to determine the effects of L-arginine and its analogues on the activity of NADPH oxidase, myeloperoxidase and inducible nitric oxide synthase. The activity of enzymes will be analysed in: i) ?chemical? system (pure enzymes), ii)
Keywords
Public support
Provider
Czech Science Foundation
Programme
Standard projects
Call for proposals
Standardní projekty 11 (SGA02008GA-ST)
Main participants
—
Contest type
VS - Public tender
Contract ID
524-08-1753
Alternative language
Project name in Czech
Vliv L-argininu a jeho analogů na tvorbu reaktivních metabolitů kyslíku a dusíku profesionálními fagocyty
Annotation in Czech
Projekt je zaměřen na studium vlivu L-argininu a jeho analogů na aktivitu myeloperoxidasy, NADPH oxidasy a inducibilní syntasy oxidu dusnatého. Aktivita těchto enzymů bude analyzována: i) v ?chemických? systémech (čisté enzymy), ii) v in vitro podmínkách
Scientific branches
Completed project evaluation
Provider evaluation
V - Vynikající výsledky projektu (s mezinárodním významem atd.)
Project results evaluation
The solutionof project brought out many valuable results that were presented at international symposiums and that served as basis for 6 publications in high impacted journals.
Solution timeline
Realization period - beginning
Jan 1, 2008
Realization period - end
Dec 31, 2012
Project status
U - Finished project
Latest support payment
Apr 1, 2012
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP13-GA0-GA-U/02:3
Data delivery date
May 17, 2016
Finance
Total approved costs
4,969 thou. CZK
Public financial support
4,969 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK
Recognised costs
4 969 CZK thou.
Public support
4 969 CZK thou.
0%
Provider
Czech Science Foundation
CEP
GJ - Diseases and animal vermin, veterinary medicine
Solution period
01. 01. 2008 - 31. 12. 2012